--- title: "NHS Framework - Blood Disorders including Haemophilia A and B - July 2024" ocid: "ocds-h6vhtk-043b0e" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-043b0e" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-043b0e.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-043b0e.json" source: "Find A Tender Service" current_stage: "Award" buyer: "NHS ENGLAND" published: "2024-06-11" --- # NHS Framework - Blood Disorders including Haemophilia A and B - July 2024 Buyer: NHS ENGLAND Current stage: Award OCID: ocds-h6vhtk-043b0e [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-043b0e) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-043b0e.json) ## Summary The public procurement contracting process is currently at the Tender stage, led by the buying organisation named [Buying Organisation]. The title of the procurement is [Title], falling under the industry category of [Industry Category]. The location for this procurement process is [Location]. Key dates and deadlines include [Key Dates/Deadlines]. This procurement opportunity presents a chance for businesses to compete for contracts with potential for growth. This tender provides opportunities for businesses in the [Industry Category] sector to expand their operations. Companies specializing in [Specific Business Type] would be well-suited to compete in this procurement process. The procurement method for this opportunity is [Procurement Method], offering a chance for businesses to showcase their capabilities and secure contracts from the contracting authority, [Buying Organisation]. ## Notice Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024 Offer reference number: CM/PHS/22/5661 Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England ### Lot Information CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII Standard Half-life Recombinant Factor VIII Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/03 Emicizumab CM/PHS/22/5661/03 Emicizumab Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL) CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL) Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL) CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL) Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL) CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL) Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/07 rFIX - Standard Half Life CM/PHS/22/5661/07 rFIX - Standard Half Life Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/08 Recombinant Factor VII CM/PHS/22/5661/08 Recombinant Factor VII Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/11 Factor IX - High Purity Factor IX CM/PHS/22/5661/11 Factor IX - High Purity Factor IX Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/12 Factor X CM/PHS/22/5661/12 Factor X Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/13 Factor XIII - Plasma Derived CM/PHS/22/5661/13 Factor XIII - Plasma Derived Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/14 Factor XIII - Recombinant CM/PHS/22/5661/14 Factor XIII - Recombinant Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/15 Von willebrands factor / Factor VIII CM/PHS/22/5661/15 Von willebrands factor / Factor VIII Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/17 Von willebrands factor - Recombinant CM/PHS/22/5661/17 Von willebrands factor - Recombinant Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/18 Fibrinogen Concentrate CM/PHS/22/5661/18 Fibrinogen Concentrate Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/19 Prothrombin Complex dried CM/PHS/22/5661/19 Prothrombin Complex dried Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/20 Protein C Concentrate CM/PHS/22/5661/20 Protein C Concentrate Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups) CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups) Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/22 Freeze Dried Plasma CM/PHS/22/5661/22 Freeze Dried Plasma Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. CM/PHS/22/5661/23 Caplacizumab CM/PHS/22/5661/23 Caplacizumab Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/018011-2024 | | Notice type | Tender Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Large, SME | | All stages | Tender, Award | ## Dates | Field | Value | | --- | --- | | Publication date | 11 Jun 2024 | | Submission deadline | 21 Mar 2024 | | Future notice date | Not specified | | Award date | 30 May 2024 | | Contract period | 30 Jun 2024 - 30 Apr 2027 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £1,168,000,000 | | Lots value | £23 | | Awards value | Not specified | | Contracts value | £1 | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Cancelled | | Awards status | Active, Unsuccessful | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | NHS ENGLAND | | Locality | LEEDS | | Post town | Leeds | | Postcode | LS2 7UE | | Country | England | | ITL 1 | TLE Yorkshire and The Humber | | ITL 2 | TLE4 West Yorkshire | | ITL 3 | TLE42 Leeds | | Local authority | Leeds | | Electoral ward | Little London & Woodhouse | | Westminster constituency | Leeds Central and Headingley | | Delivery location | Not specified | ## Supplier | Field | Value | | --- | --- | | Number of suppliers | 9 | | Supplier names | BIO PRODUCTS LABORATORY; CSL BEHRING; LFB; NOVO NORDISK; OCTAPHARMA; PFIZER; ROCHE PRODUCTS; SOBI (SWEDISH ORPHAN BIOVITRUM; TAKEDA | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products ## Release History - 11 Jun 2024 at 13:27 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/018011-2024 - 24 May 2024 at 08:06 - TenderUpdate - Tender Notice - https://www.find-tender.service.gov.uk/Notice/016397-2024 - 19 Feb 2024 at 11:12 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/005350-2024 ## Notice URLs - https://health-family.force.com/s/Welcome - https://www.england.nhs.uk// - https://www.judiciary.uk/courts-and-tribunals/high-court/ ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-043b0e. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-043b0e.json.